September 2016 FDA Recall Drug by Teva Pharmaceuticals Usa
D-0095-2017 - Failed Impurities/Degradation Specifications

This Class III drug recall was voluntarily initiated by Teva Pharmaceuticals Usa on September 13, 2016 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0095-2017

Reason for Recall
Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.
Initiated
09-13-2016
Reported
10-19-2016
Quantity
11,214 vials

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Teva Pharmaceuticals USA
mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Batch or Lot Expiration Information

Lot# Lot Numbers: 31318574B, Exp 09/16; 31319610B, Exp 07/17; 31320058B, Exp 11/17; 31320497B, Exp 12/17; 31320744B, Exp 02/18